Method Scope
Related substances testing quantifies impurities present in a drug product, whether carried over from the drug substance's own synthesis, formed through degradation during manufacturing and storage, or arising from interaction with excipients, distinguishing this testing from residual solvent or elemental impurity testing which address different, distinct impurity categories with their own dedicated ICH frameworks. A related substances method needs to reliably separate and quantify every impurity considered relevant to the specific product, whether identified by name or, where full identification has not been achieved, tracked consistently by its relative retention characteristics, across the product's full proposed shelf life and under realistic storage conditions.
Detection Approach
Related substances methods most commonly use HPLC with ultraviolet detection, chosen for its broad applicability, established regulatory acceptance, and generally adequate sensitivity for the concentration ranges typically relevant to drug product impurity control. Method development should confirm the detection wavelength selected provides adequate, balanced sensitivity across the parent drug and all impurities of interest, since a wavelength optimized purely for the parent compound's own maximum absorbance can sometimes provide meaningfully poorer sensitivity for a structurally different impurity that absorbs less strongly at that same specific wavelength. Where impurities show significantly different UV response relative to the parent drug, individual relative response factors should be established and applied during quantification, rather than assuming a uniform response factor of one across every impurity regardless of its own actual detector response characteristics.
Quantification Strategy
Impurities are typically quantified either against an external reference standard for the specific impurity where a genuine, characterized standard is available, or, more commonly for less characterized or unavailable impurities, against the parent drug's own peak area using an established or default relative response factor, with quantification approach selected and validated specifically for each individual impurity based on standard availability and any confirmed difference in detector response. This quantification approach should be documented explicitly and consistently applied, since switching quantification approach for the same impurity between different testing occasions, without clear justification, can introduce an artificial, method-driven apparent inconsistency in reported impurity levels across a product's stability program that has nothing to do with genuine product degradation.
Reporting Thresholds
ICH Q3B establishes reporting, identification, and qualification thresholds scaled to the product's maximum daily dose, meaning smaller-dose products generally carry higher percentage thresholds before an impurity must be individually reported, identified, or toxicologically qualified, reflecting that the same percentage impurity level represents a meaningfully smaller absolute patient exposure at a lower product dose. Method sensitivity should be confirmed adequate to reliably detect and quantify impurities at least down to the applicable reporting threshold for the specific product's own dose, since a method lacking this sensitivity could allow a genuinely reportable impurity level to go undetected and unreported entirely.
Specificity and Stability-Indicating Capability
Because related substances methods are typically also relied upon as the product's primary stability-indicating method, specificity demonstration through forced degradation studies is a required, integral part of related substances method validation, confirming the method can distinguish the intact parent drug from every degradation product genuinely capable of forming under realistic storage conditions. A related substances method validated only for specificity against known synthesis-related impurities, without also confirming specificity against genuine degradation products generated through forced degradation, provides an incomplete validation package relative to what the method's actual intended stability-monitoring use requires.
System Suitability Requirements
System suitability criteria for related substances methods typically require adequate resolution between the parent drug peak and its closest-eluting known impurity, along with appropriate sensitivity confirmation, commonly through a diluted standard solution representative of the applicable reporting threshold, run at the start of each testing sequence to confirm the system is performing adequately before any actual sample results are generated and relied upon. These system suitability requirements should be derived directly from the method's own validation data, not set as a generic, disconnected value applied uniformly regardless of what the specific method's own demonstrated resolution and sensitivity performance actually supports.
Handling an Unknown Impurity
Where a chromatographic peak is detected above the reporting threshold but cannot be attributed to any known, previously characterized impurity, further identification work, often involving mass spectrometry or other complementary structural techniques, is generally warranted once the peak's level approaches the identification threshold, since an unidentified impurity above this threshold cannot be adequately toxicologically qualified or otherwise assessed for genuine patient safety relevance without first establishing its actual chemical identity.
Leave your rating